RT @FlagshipPioneer: “We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing…

We're excited to be back in San Francisco for #JPM2025! Join Seres Therapeutics on Thursday, January 16th at 7:30 AM PST for a company overview highlighting our plans to advance our pipeline, including SER-155.

Today we're thrilled to announce that our lead live biotherapeutic, SER-155, has received Breakthrough Therapy Designation from the FDA for the reduction of blood stream infections in adults undergoing an allogeneic stem cell transplant. Read more:

Our CEO Eric Shaff will be participating in a fireside chat at the upcoming Piper Sandler Annual Healthcare Conference on December 3rd. Read the release:

Today we reported our Q3 financial results and provided business updates, including planned next steps for SER-155 following encouraging Phase 1b data in allo-HSCT patients. Read more in the full release:

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release:

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days. Read the full release:

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together, but we helped raise money to support our local #SpecialOlympics athletes! Learn more about the cause:  

Today, we entered into an agreement w/ partner @NestleHealthUS to acquire Vowst, a deal that allows us to focus on our pioneering mission of advancing revolutionary microbiome therapeutics for as many patients as possible.

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am CDT. Learn more:

Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo #HSCT patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation.

We are excited to present at #TANDEM24 in San Antonio. Join us at the poster session on Feb 22nd at 6:45pm CST to learn about preliminary data from our currently enrolling Phase 1b study of investigational #microbiome therapeutic SER-155. Learn more:

At Seres, we have been pioneering the development of microbiome therapeutics since 2011. As a #FlagshipFounded company, we took bold leaps in 2023 to transform the lives of patients as we received FDA approval for the first orally administered microbiome-based therapeutic. We're #SeresProud to reflect on this past year alongside other #FlagshipFounded companies and very excited to help patients who have potentially life-threatening disease in the year ahead.

Attention #FierceNPP attendees! Join our Chief Commercial & Strategy Officer Terri Young today at 9:00AM ET to hear insights and best practices drawn from her experience. #SeresProud @LifeSciEvents

We’re #SeresProud to celebrate the grand opening of our new CLIA lab with a ribbon-cutting ceremony in Lower Gwynedd, Pa. This new donor screening facility will allow us to continue our mission to transform patients’ lives by revolutionizing #microbiome therapeutics.

Can new advancements in #microbiome therapeutics change how we fight anti-microbial resistance (#AMR)? Join Seres’ Chief Scientific Officer Matthew Henn (@microbiologic) & team at @AMRCongress to discuss potential solutions. See details: #WorldAMRCongress

Antimicrobial resistance (#AMR) is one of our greatest public health threats, and the situation is worsening. In @statnews we explain why innovative #microbiome therapeutic options may be important for combating antibiotic resistance:

We’re on a mission to revolutionize #microbiome therapeutics. This summer, all of our teams came together to collaborate on achieving our goals to better serve patients and celebrate our progress to date. We couldn’t be more #SeresProud of our team!

Join our presentation today at 3 PM EDT at @CG_Driven’s 43rd Annual Growth Conference. Can’t make it? An audio webcast will be available on our website:

Alongside our collaborator, Nestle Health Science, we are executing the launch our oral microbiome therapy in the United States. In today’s Q2 2023 earnings report, we were pleased to announce highly encouraging initial launch results.